Atrial natriuretic peptide is not degraded by the lungs in humans.
In an attempt to identify and quantify the sites of atrial natriuretic peptide (ANP) degradation, particularly the lungs, a new tracer method to study ANP metabolism in vivo in humans was developed and applied to patients with left ventricular dysfunction. Thirteen male, normotensive, cardiac patients with different degrees of left ventricular myocardial involvement were enrolled in the study. The study protocol required constant infusion (3 patients) or bolus injection (10 patients) of 125I-labeled ANP just upstream of the right atrium and blood sampling from different sites (pulmonary artery, aorta, inferior vena cava, and femoral vein) during the hemodynamic study. Data analysis was based on a kinetic model consisting of three blocks in series (right heart, lungs and left heart, and periphery) supplied by the same plasma flow (plasma cardiac output). Plasma levels of native ANP were measured with a sensitive and specific immunoradiometric assay method. ANP values measured in the aorta (163.9 +/- 144.8 pg/mL, n = 80) were superimposable on those measured in the pulmonary artery (161.8 +/- 136.5 pg/mL, n = 80). Negligible extraction of 125I-labeled ANP was found in the lungs and left heart block (on average 0.08 +/- 3.92%), whereas the peripheral block extraction (46.2 +/- 7.8%) accounted for almost total hormone removal from the blood (whole body extraction was 46.4 +/- 6.6%). ANP metabolic clearance rate (3.11 +/- 1.48, range 1.4-6.8 L/min) declined with the progression of left ventricular dysfunction (plasma cardiac output 3.46 +/- 1.08, range 1.2-5.7 L/min), and a close correlation between metabolic clearance rate and cardiac output was evident. Our data suggest that lungs do not extract, or extract only very small amounts, of labeled ANP administered iv to patients with different degrees of left ventricular myocardial involvement, and whole body extraction of labeled ANP remains relatively stable with the progression of disease, and the large reductions in clearance values observed in our patients can be ascribed mainly to the reductions in cardiac output.
Iervasi
G
G
Laboratory of Cardiovascular Endocrinology, Consiglio Nazionale delle Ricerche Institute of Clinical Physiology, Pisa, Italy. iervasi@nsifc.ifc.pi.cnr.it
Clerico
A
A
Pilo
A
A
Sabatino
L
L
Manfredi
Forini
F
F
Del Chicca
M G
MG
Palmieri
C
C
Ravani
M
M
Donato
L
L
D000328:Adult; D001011:Aorta; D009320:Atrial Natriuretic Factor / Q000097:blood / Q000378:metabolism*; D002302:Cardiac Output; D005268:Femoral Vein; D006439:Hemodynamics; D006801:Humans; D007457:Iodine Radioisotopes; D007700:Kinetics; D008168:Lung / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D011651:Pulmonary Artery; D014682:Vena Cava, Inferior; D018487:Ventricular Dysfunction, Left / Q000378:metabolism* / Q000503:physiopathology
D007457:Iodine Radioisotopes; D009320:Atrial Natriuretic Factor